Type 2 diabetes mellitus and cardiovascular disease. Part II. Recommendations for the treatment of major cardiovascular diseases associated with diabetes

Authors

  • S.M. Koval State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
  • K.O. Yushko State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.14.1.2021.227397

Keywords:

type 2 diabetes mellitus, cardiovascular disease, coronary heart disease, heart failure, arrhythmias, peripheral arterial disease

Abstract

The comorbid course of diabetes mellitus and cardiovascular diseases is one of the pathological conditions that physicians of the therapeutic profile of all levels often encounter in their practice. This association of diseases burdens each other, leads to more rapid and severe damage to target organs, cardiovascular complications, disability, and death, and requires modern drug approaches to the treatment. The article provides data on the main provisions of modern recommendations for the treatment of cardiovascular diseases occurring in combination with diabetes mellitus, based on the latest documents of European and American experts in the field of diabetology and cardiology.

References

Коваль С.М., Юшко К.О. Цукровий діабет 2 типу та серцево-судинні захворювання. Частина І. Визначення проблеми, стратифікація кардіоваскулярного ризику і основні напрямки профілактики серцево-судинних захворювань у хворих на цукровий діабет 2 типу. Артериальная гипертензия. 2020. № 13(5). С. 11-19.

Cosentino F., Grant P.J., Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020 Jan 7. № 41(2). Р. 255-323. doi: 10.1093/eurheartj/ehz486.

Diabetes in cardiovascular disease: to Braunwald’s heart sisease. Ed. by Darren K. McGuire, Nikolaus Marx. Elsevier, 2015. 398 р.

Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа, 2014. 1032 с.

Коваль С.М., Снігурська І.О., Пенькова М.Ю., Мисниченко О.В., Літвінова О.М., Юшко К.О. Сучасні підходи до медикаментозного контролю артеріальної гіпертензії у хворих на цукровий діабет. Раціональна фармакотерапія. 2018. № 2(47). С. 24-33.

Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2019. doi: 10.1093/eurheartj/ehz425.

Колесникова Е.В., Козырева Т.Е. Особенности метаболического профиля пациентов с ассоциированным течением ишемической болезни сердца и сахарного диабета 2 типа, инфицированных Helicobacter pylori. Український терапевтичний журнал. 2016. № 3. Р. 34-39.

Ibanez B., James S., Agewall S. et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018. № 39. Р. 119-177.

Davies M.J., D’Alessio D.A., Fradkin J., Kernan W.N., Mathieu C., Mingrone G., Rossing P., Tsapas A., Wexler D.J., Buse J.B. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec. № 41(12). Р. 2669-2701. doi: 10.2337/dci18-0033.

Zelniker T.A., Wiviott S.D., Raz I. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019. № 139. Р. 2022-2031.

Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019. № 393. Р. 31-39.

Valgimigli M., Bueno H., Byrne R.A. et al.; ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018. № 39. Р. 213-260.

Neumann F.J., Sousa-Uva M., Ahlsson A. et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur. Heart J. 2019. № 40. Р. 87-165.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016. № 37. Р. 2129-2200. doi: 10.1093/eurheartj/ehw128.

Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016. № 37. Р. 2893-2962.

Старченко Т.Г., Коваль С.М., Юшко К.О., Шкапо В.Л., Милославський Д.К. Формування порушення ритму серця у хворих на артеріальну гіпертензію з цукровим діабетом 2 типу. Вісник проблем біології і медицини. 2018. № 3(145). С. 42-46.

Priori S.G., Blomstrom-Lundqvist C., Mazzanti A. et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardio­logy (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 2015. № 36. Р. 2793-2867.

Aboyans V., Ricco J.B., Bartelink M.E.L. et al.; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur. Heart J. 2018. № 39. Р. 763-816.

Hinchliffe R.J., Brownrigg J.R., Andros G. et al.; International Working Group on the Diabetic Foot. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab. Res. Rev. 2016. № 32. Р. 136-144.

Hussain M.A., Bin-Ayeed S.A., Saeed O.Q., Verma S., Al-Omran M. Impact of diabetes on carotid artery revascularization. J. Vasc. Surg. 2016. № 63. Р. 1099-1107.e4.

Published

2021-04-08

Issue

Section

To help clinicians